<DOC>
	<DOCNO>NCT01286233</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient breast cancer may help doctor learn change occur DNA identify biomarkers related fatigue . PURPOSE : This research study study biomarkers associate fatigue patient early-stage breast cancer treat metformin placebo NCIC-CTG-MA.32 .</brief_summary>
	<brief_title>Study Biomarkers Associated With Fatigue Patients With Early-Stage Breast Cancer Treated With Metformin Placebo NCIC-CTG-MA.32</brief_title>
	<detailed_description>OBJECTIVES : - To prepare , separate component , store blood specimen NSABP Serum Bank Baylor College Medicine Breast Center future DNA , RNA , plasma analysis , analyze specific proinflammatory cytokine , genetic polymorphism , RNA expression array collaborate laboratory University California , Los Angeles ( UCLA ) . - To examine association marker inflammation symptom fatigue among patient without exposure metformin hydrochloride . - To examine relationship single nucleotide polymorphism ( SNPs ) promoter region IL-1 IL-6 symptom fatigue without exposure metformin hydrochloride . - To examine RNA expression profile relationship fatigue compare pattern expression patient without exposure metformin hydrochloride . - To determine biological behavioral predictor fatigue breast cancer patient five year post-randomization . - To determine whether metformin associate reduction inflammatory marker correspond decrease fatigue . ( Exploratory ) OUTLINE : This multicenter study . Patients ' serum plasma , collect baseline 6 , 12 , 24 month NCIC CTG MA.32 randomization , analyzed inflammatory marker , DNA polymorphism , RNA expression array ELISA , TaqMan PCR , RT-PCR . Patients complete Fatigue Symptom Inventory ( symptom associate fatigue , sleep disturbance , depression , endocrine therapy ) baseline periodically study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion Criteria The patient must consent participate must sign dated appropriate IRBapproved consent form conform federal institutional guideline MA.32.F Study enrol . The patient must female . The patient must reside United States Canada . The patient must Englishspeaking . The patient must eligible randomization MA.32 treatment trial . ( Participation MA.32 QOL study permit require . ) The patient must start take MA.32 study therapy . The patient must complete primary breast radiation therapy least two week prior enrollment MA.32.F . Exclusion Criteria MA.32 study therapy initiate . Currently receive radiation therapy additional radiation therapy plan initiation start MA.32 study therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>fatigue</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>depression</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>